Minerva Neurosciences Earnings Call Transcripts
Fiscal Year 2026
-
Roluperidone aims to address primary negative symptoms in schizophrenia through a paradigm-shifting monotherapy approach, with a robust phase III trial underway and key efficacy data expected in 2027. The program is supported by strong IP and ongoing FDA engagement.
-
Attendees approved all six proposals, including director elections, amendments to the certificate of incorporation, executive compensation, and auditor ratification. No questions were submitted, and voting results will be reported on Form 8-K.
-
Negative symptoms in schizophrenia remain a major unmet need, with roluperidone showing promise as a monotherapy that improves both symptoms and functioning without typical antipsychotic side effects. The pivotal trial is underway, with top-line results expected in the second half of next year.
-
Negative symptoms in schizophrenia remain a major unmet need, with roluperidone showing promise in improving both symptoms and daily functioning. The ongoing confirmatory phase III trial, supported by strong FDA engagement and $200 million in financing, aims to validate these results and enable U.S. launch.
-
The event detailed the clinical and regulatory progress of roluperidone for negative symptoms in schizophrenia, highlighting robust efficacy, low relapse rates, and a strategic phase III trial design. Experts emphasized the drug's unique mechanism and potential for broader indications, with strong investor and FDA support.